Neoadjuvant systemic therapy (NST) has become the first-line treatment for locally advanced breast cancers and for selected cases of early-stage breast cancer. [1,2]. In addition to NST, the effectiveness of neoadjuvant endocrine therapy is being investigated in hormone receptor positive tumors. Furthermore, targeted therapies such as CDK4/6, PARP, and immune checkpoint inhibitors are under investigation [3,4].